Client Testimonials

“Novateur engaged the appropriate thought leaders and helped us understand the market and its challenges and the appropriate path through development that would support the positioning of our asset to allow us to capture value and was invaluable to our decision making process.
More than anything, Novateur has taught us that being first-in-class is not enough and that you need to have a well thought out plan to execute on.”

Michael L. Gallo, PhD

President, Innovative Targeting Solutions

“Having seen pitch decks of young companies before and after they’ve worked with Novateur, I can tell you that there’s been a transformative strategic focus. That focus can mean the difference between success & failure.”

Dr. Shermaine Tilley

Managing Partner, CTI

“The Novateur Ventures’ team guided us to the next level, bringing knowledge, experience and credibility to our team. Simply put, it was like having a world class scientific advisory board, BD team, drug development team simultaneously!”

Dr. Frederic Leduc

Co-founder & CEO, Immune Biosolutions

“Novateur’s team demonstrated the deep clinical and regulatory knowledge required for our start-up with the flexibility of engagement to drive success for our company.”

Parimal Nathwani

Vice President, Commercialization, TIAP – Toronto Innovation Acceleration Partners (formerly MaRS Innovation)

“Novateur’s experience in tackling difficult manufacturing problems is unparalleled, they bring a wealth of wisdom and enthusiasm to the team. It’s been a pleasure working with Novateur.”

Dr. Amanda Malone

Co-founder & CSO, Eupraxia Pharmaceuticals

“The Novateur Team has accelerated our development path far beyond our initial expectations. They are highly responsive and truly know how to create value in companies.”

Dr. Sandra Dunn

CEO, Phoenix Molecular Designs

“Novateur’s vast and knowledgeable advisors have been instrumental in enabling our success in development and commercialization of our pipeline and our recent IPO. We highly recommend them.”

Amir Avniel

Co-Founder, COO & President, Beyond Air

“Novateur team were able to help us address a number of critical commercial and regulatory issues facing one of our start-up companies working in the cell therapy field. Novateur delivered actionable recommendations that allowed us to deliver a clear and complete business plan to potential investors.”

Steven J. Klein, PhD, MBA

Vice-President, Business Development, IRICoR

“Novateur team has been of a tremendous help for us to achieve a transition from a technology company to a therapeutic company. They are a deeply experienced team and it is easy and fun working with them… they genuinely care about your project.”

Dr. Francois-Thomas Michaud

CEO, Feldan Therapeutics

“The Novateur team and the diabetes expertise of Dr. Thomas Stephens have been very helpful in developing Zucara’s clinical trial plan for a novel drug to prevent hypoglycemia (low blood sugar) in diabetes patients. The ability to get advice from a group with the right experience and track record specific to our disease focus makes a big difference.”

Michael Midmer

CEO, Zucara

“Navigo Proteins discovers and develops innovative proteins for theranostic applications. Novateur is our partner of choice for the identification, evaluation and realization of indication specific projects. For this purpose Novateur provides a network of highly professional and experienced pharmaceutical experts. In close co-operation with Novateur we develop and realize precisely tailored projects that translate our technological assets into viable products. Novateur’s services include scientific and strategic as well as public and private financing support. Novateur ideally complements Navigo’s capacities to guarantee a seamless transition of early discovery into pre-clinical and clinical development based on a sound and focused business case.
We are looking forward to continue and expand our partnership with Novateur.”

Dr. Henning Afflerbach

Managing Director, Navigo Proteins

“We reached out to Novateur to help us navigate the numerous potential indications we could pursue for a molecule we were working with, using our oral drug delivery technology. Their expertise, guidance and thorough review of the possibilities was well researched, resulting in two recommendations, one of which we now intend to implement”

Brian Zietsman

President & CFO, Enteris BioPharma